Pediatr Gastroenterol Hepatol Nutr. 2012 Dec;15(4):237-42. doi: 10.5223/pghn.2012.15.4.237. Epub 2012 Dec 31.
Efficacy of Proton Pump Inhibitor-based Triple Therapy and Bismuth-based Quadruple Therapy for Helicobacter pylori Eradication in Korean Children.
Pediatric gastroenterology, hepatology & nutrition
Jeana Hong, Hye Ran Yang
Affiliations
Affiliations
- Department of Pediatrics, Kangwon National University Hospital, Chuncheon, Korea. ; Department of Pediatrics, Seoul National University Bundang Hospital, Seongnam, Korea.
PMID: 24010093
PMCID: PMC3746056 DOI: 10.5223/pghn.2012.15.4.237
Abstract
PURPOSE: The aim of this study was to assess and compare the efficacies of proton pump inhibitor-based triple therapy and bismuth-based quadruple therapy as first-line treatments for Helicobacter pylori eradication in Korean children.
METHODS: We retrospectively reviewed the data of children who had been diagnosed with H. pylori infection at the Seoul National University Bundang Hospital from March 2004 to August 2012. The patients were randomly assigned to receive either triple therapy consisting of omeprazole, amoxicillin, and clarithromycin for 2 weeks (OAC group) or quadruple therapy comprising omeprazole, amoxicillin, metronidazole, and bismuth salts for 1 week (OAMB group). The patients were evaluated for eradication of H. pylori infection at 4 weeks after the completion of the treatment.
RESULTS: Of the 129 children enrolled in this study, 118 (91.5%) were included in the final analysis. The eradication rates in OAC and OAMB groups were 67.7% (42/62) and 83.9% (47/56), respectively, which were significantly different between the 2 treatment groups (p=0.041). The eradication rates in the OAMB group during the periods 2004-2006, 2007-2009, and 2010-2012 were superior to those in the OAC group.
CONCLUSION: This study indicated that the 1-week bismuth-based quadruple therapy, compared with the standard 2-week triple therapy, was significantly more successful in eradicating H. pylori infection in Korean children.
Keywords: Child; Disease eradication; Helicobacter pylori; Therapeutics
References
- Antimicrob Agents Chemother. 2001 Jul;45(7):2134-5 - PubMed
- Eur J Gastroenterol Hepatol. 2006 May;18(5):511-4 - PubMed
- Korean J Gastroenterol. 2011 Dec;58(2):67-73 - PubMed
- J Pediatr Gastroenterol Nutr. 2011 Aug;53(2):230-43 - PubMed
- Korean J Gastroenterol. 2006 May;47(5):337-49 - PubMed
- J Clin Gastroenterol. 2010 Sep;44(8):536-43 - PubMed
- J Pediatr Gastroenterol Nutr. 2000 Nov;31(5):490-7 - PubMed
- Dig Dis Sci. 2009 Aug;54(8):1720-4 - PubMed
- Helicobacter. 2007 Apr;12(2):150-6 - PubMed
- Am J Gastroenterol. 2003 Mar;98(3):562-7 - PubMed
- Gut. 2010 Aug;59(8):1143-53 - PubMed
- Korean J Gastroenterol. 2009 Nov;54(5):269-78 - PubMed
- J Korean Med Sci. 2006 Dec;21(6):1037-40 - PubMed
- Gastroenterology. 2002 Dec;123(6):1763-9 - PubMed
- Eur J Intern Med. 2013 Jan;24(1):16-9 - PubMed
- World J Gastroenterol. 2008 Dec 28;14(48):7361-70 - PubMed
- Eur J Pediatr. 2013 Nov;172(11):1427-34 - PubMed
- N Engl J Med. 2002 Oct 10;347(15):1175-86 - PubMed
- Korean J Gastroenterol. 2005 Nov;46(5):368-72 - PubMed
- Gut. 2006 Dec;55(12):1711-6 - PubMed
- Gut. 2012 May;61(5):646-64 - PubMed
- J Gastroenterol Hepatol. 2005 Feb;20(2):264-9 - PubMed
Publication Types